Zentaris, the German cancer research company, was forced to indefinitely postpone its Eu200m IPO this week, at the same time as Ethypharm was trying to brighten up the biotech market with the launch of its own IPO. Zentaris, which was due to be spun out of German chemicals group Degussa, was expected to price its IPO last Monday. However, the deal was hit by bad news coming from Praecis Pharmaceuticals, a US-based comparable for Zentaris. Praecis's shares fell 44% on the news that its application for Plenaxis, a hormonal treatment for prostrate cancer, had been rejected because of inadequate information.
June 22, 2001